The antiapoptotic protein HAX-1 (HS-associated protein X-1) localizes to sarcoplasmic reticulum (SR) in the heart and interacts with the small membrane protein phospholamban (PLN), inhibiting the cardiac sarco/endoplasmic reticulum calcium ATPase 2a (SERCA2a) in the regulation of overall calcium handling and heart muscle contractility. However, because global HAX-1 deletion causes early lethality, how much endogenous HAX-1 contributes to PLN's inhibitory activity on calcium cycling is unknown. We therefore generated a cardiacspecific and inducible knock-out mouse model. HAX-1 ablation in the adult heart significantly increased contractile parameters and calcium kinetics, associated with increased SR calcium load. These changes occurred without any changes in the protein expression of SERCA2a, PLN, and ryanodine receptor or in the PLN phosphorylation status. The enhanced calcium cycling in the HAX-1-depleted heart was mediated through increases in the calcium affinity of SERCA2a and reduced PLN-SERCA2a binding. Comparison of the HAX-1 deletion-induced stimulatory effects with those elicited by PLN ablation indicated that HAX-1 mediates ϳ50% of the PLN-associated inhibitory effects in the heart. Stimulation with the inotropic and lusitropic agent isoproterenol eliminated the differences among wild-type, HAX-1-deficient, and PLN-deficient hearts, and maximally stimulated contractile and calcium kinetic parameters were similar among these three groups. Furthermore, PLN overexpression in the HAX-1-null cardiomyocytes did not elicit any inhibitory effects, indicating that HAX-1 may limit PLN activity. These findings suggest that HAX-1 is a major mediator of PLN's inhibitory activity and a critical gatekeeper of SR calcium cycling and contractility in the heart.
Depressed sarcoplasmic reticulum (SR) 2 calcium transport, associated with impaired cardiomyocyte calcium cycling and contractility, is a major characteristic of human and experimental heart failure (1, 2) . SR Ca 2ϩ transport is mediated by the cardiac isoform of the sarco/endoplasmic reticulum Ca 2ϩ -ATPase 2a (SERCA2a), which is one of the most abundant proteins in the heart. SERCA2a is regulated by a small integral membrane, phospholamban (PLN), phosphorylation of which during fightor-flight responses relieves its inhibitory effects, enhancing cardiac function (3) . Over the last several decades, PLN and SERCA2a have been characterized in great detail by an abundance of biochemical and biophysical studies (3) . An elegant structure-function model has been generated in which PLN stabilizes a conformation of SERCA2a with a low Ca 2ϩ affinity, thus decreasing enzymatic activity (4) . From the physiological perspective, the role of PLN in cardiac function has been elucidated by the generation and characterization of genetically altered mouse models. Ablation of PLN was associated with enhanced Ca 2ϩ cycling and contractile parameters, resulting in an overall hypercontractile cardiac function (5, 6) , which persisted throughout aging (7) . In contrast, overexpression of PLN in the heart resulted in depressed calcium kinetics and contractile parameters, but the inhibitory effects were relieved upon PLN phosphorylation by ␤-adrenergic agonists (8, 9) . However, accumulating evidence indicates that regulation of SR Ca 2ϩ -transport is more complicated than we originally perceived, and there are several proteins that physically interact with PLN and may modulate cardiomyocyte Ca 2ϩ handling (1, 10) . One of these proteins is HAX-1 (HS-associated protein X-1), which has been found to directly interact with PLN (11) and modulate its activity (13) .
HAX-1 is an ϳ35-kDa protein that is ubiquitously expressed at the mitochondria with critical anti-cell death function in immune and neuronal cells (14) . These effects carry over into the heart, where HAX-1 can regulate cell death through endoplasmic reticulum stress (15) and mitochondrial stability (16) in myocardial ischemia reperfusion injury. In cardiomyocytes, HAX-1 also localizes to SR in addition to its ubiquitous mitochondrial localization, where it interacts with PLN (13) via AA 203-245 in HAX-1 and AA 16 -22 in PLN (11) . Phosphoryla- cro ARTICLE tion of PLN by protein kinase A during ␤-agonist stimulation results in dissociation of HAX-1 from PLN (11), suggesting a physiological relevance of this interaction. Previous work has shown that HAX-1 overexpression increases inhibition of SERCA2a by PLN and depresses contractility, whereas decreased expression of HAX-1 had the opposite effects (13, 15) . Interestingly, loss of HAX-1 protein as a result of human mutations causes severe neutropenia, a rare immunodeficiency disease (14) . In the mouse, global genetic deletion of HAX-1 associates with a short life span because of progressive loss of neuronal cells (14) . Thus, the impact of HAX-1 deficiency in the heart and specifically on SERCA2a/PLN activity is not currently clear.
The present study was designed to delineate the role of endogenous HAX-1 on SR Ca 2ϩ transport through the generation and characterization of a cardiac specific and inducible knock-out mouse model. We demonstrate for the first time that HAX-1 ablation relieves approximately 50% of the PLN inhibitory effects on SR Ca 2ϩ transport, cardiomyocyte Ca 2ϩ cycling, and contractile parameters. These findings suggest that endogenous HAX-1 is a critical regulator of PLN regulation and underline the significant function of this protein in the heart.
Results
Inducible HAX-1 ablation in the adult heart does not elicit compensatory changes in SR Ca 2؉ -handling proteins
Overexpression of HAX-1 in the heart has been shown to decrease Ca 2ϩ cycling through increases in PLN inhibition, and these regulatory effects of HAX-1 are abrogated in the absence of PLN (13) . Because global ablation of HAX-1 results in early lethality (17), we generated a cardiac-specific and inducible HAX-1 knock-out model (HAXiKO) to delineate the full contribution of endogenous HAX-1 in the heart. This was achieved by crossing a mouse with a floxed HAX-1 gene (17) with an ␣-myosin heavy chain mer-cre-mer transgenic mouse, which produces a cardiac specific cre recombinase activity upon tamoxifen treatment. Tamoxifen treatment was initiated at 2 months of age, and full cardiac ablation of HAX-1 was achieved after 14 days of tamoxifen (Fig. 1A ). 14 days after termination of this treatment, we assessed the expression levels of SERCA2a, PLN, and ryanodine receptor (RyR). There were no differences between HAXiKO and WT hearts (Fig. 1, A and B) . In addition, the levels of PLN phosphorylation at either Ser 16 or Thr 17 were similar (Fig. 1, A and B) . These results indicate that any functional changes associated with HAX-1 ablation are not due to alteration of these SR Ca 2ϩ -handling proteins.
Ablation of HAX-1 relieves 50% of PLN inhibition on cardiac contractile and Ca 2؉ -kinetic parameters
Overexpression of HAX-1 was previously shown to reduce cardiac contractility at the cellular level (13) . To examine the function of endogenous HAX-1, cardiomyocytes were isolated from HAXiKO and WT mice, and contractile parameters were assessed by video edge detection (Fig. 2, A-C) . It was observed that the fractional shortening and the rates of contraction and relaxation (ϩdL/dt and ϪdL/dt) were significantly increased in HAX-1-deficient cells, compared with WT controls (Fig. 2,  D-F) . In parallel studies, we included the PLNKO as an additional control, representing full relief of PLN inhibition and maximal SERCA2a activity (Fig. 2, D-F) . The relative increases in the HAXiKO parameters were approximately half of those achieved in PLNKO cells. In addition, isoproterenol stimulation eliminated the differences between WT, HAXiKO, and (Fig. 3, D-F) . Isoproterenol stimulation also eliminated the differences between WT, HAXiKO, and PLNKO groups. The SR Ca 2ϩ load, assessed by the caffeine-induced Ca 2ϩ -peak, was higher in the HAXiKO cardiomyocytes (Fig. 3G) . However, the decay rate of the caffeineinduced Ca 2ϩ release was not altered, reflecting no alterations in Na/Ca 2ϩ exchanger (NCX) activity (Fig. 3H) . Furthermore, the increases in SR Ca 2ϩ load by HAX-1 ablation were ϳ50% of those observed in PLNKO cells (Fig. 3G ) without any differences in the decay time of the caffeine-induced Ca 2ϩ -signal ( Fig. 3H ), indicating no alterations in NCX activity. These findings demonstrate that endogenous HAX-1 mediates ϳ50% of the PLN inhibitory effects in Ca 2ϩ cycling and contractility in the cardiac myocytes.
HAX-1 deficiency increases the Ca 2؉ affinity of SERCA2a through decreased PLN binding
To determine whether the alterations in cardiomyocyte Ca 2ϩ kinetics reflect alterations in SR Ca 2ϩ transport, we assessed the effects of HAX-1 ablation on the initial rates of oxalate-supported SR Ca 2ϩ uptake over a wide range of Ca 2ϩ concentrations, similar to those present in the cardiomyocyte during relaxation and contraction (Fig. 4A ). HAX-1 ablation resulted in significant increases in Ca 2ϩ -transport rates but had no effect on the maximal velocity of the uptake system (WT, 80.1 Ϯ 2.2 nmol/mg/min versus HAXiKO, 79.4 Ϯ 2.8 nmol/mg/ min, n ϭ 4). Analysis of the EC 50 value of Ca 2ϩ transport for Ca 2ϩ indicated that this parameter was decreased by 32% in the HAX-1 ablated hearts relative to WTs (Fig. 4B ). In addition, PLN ablation resulted in 53% reduction of the EC 50 (Fig. 4 , A and B), suggesting that HAX-1 may mediate approximately half of the PLN inhibitory effects on SERCA2a activity. These alterations at the subcellular level reflect the increased functional parameters in cardiomyocytes (Figs. 2 and 3) . The observed decrease in EC 50 of HAX-1 knock-out hearts was not associated with changes in PLN levels or PLN phosphorylation (Fig. 1, A  and B) . To test whether HAX-1 ablation may alter the interaction between SERCA2a and PLN, WT, and HAXiKO, cardiac homogenates were subjected to co-immunoprecipitation experiments, using SERCA2a as bait. Indeed, HAX-1 ablation decreased the amount of PLN pulled down by SERCA2a (Fig. 4, C and D) , consistent with reduced PLN inhibition and increased SR Ca 2ϩ -uptake rates (Fig. 4, A and B) .
Increased PLN expression does not alter contractile parameters in the absence of HAX-1
The observed decreased interaction between PLN and SERCA2a in the HAX-1 ablated hearts (Fig. 4, C and D) could be also attributed to lower affinity between these two proteins in the absence of HAX-1. In this case, increased PLN expression should be able to overcome the reduced binding and diminish the effects of HAX-1 ablation on the hypercontractile phenotype. To test this hypothesis, isolated cardiomyocytes from WT and HAXiKO mice were infected with either adenoviral GFP (ad.GFP) or PLN (ad.PLN), and the contractile parameters were then assessed. Overexpression of PLN in WT cells depressed fractional shortening, ϩdL/dt, and ϪdL/dt compared with ad.GFP control (Fig. 5, A-C) . Interestingly, the depressed parameters were similar to those observed in cardiomyocytes Cardiac HAX-1 mediates half of phospholamban inhibition isolated from hearts with 2.5-fold overexpression of PLN (PLNOE), which we had previously observed to functionally saturate inhibition by PLN (9) . However, PLN overexpression in HAXiKO cardiomyocytes had no effect on contractile parameters (Fig. 5, A-C) . In parallel control experiments, PLN overexpression was also able to reduce function in HAXOE and PLNKO cells (Fig. 5, A-C) . These results indicate that in the absence of HAX-1, endogenous levels of PLN have a functionally saturating effect on SR Ca 2ϩ cycling and contractile parameters.
Discussion
This study presents the first evidence that endogenous HAX-1 mediates approximately half of the PLN inhibitory effects and serves as a gatekeeper for PLN activity in the heart. Elucidation of the functional role of HAX-1 is of paramount importance because human mutations have been identified that result in loss of this protein (8) . The human carriers present with severe neutropenia (14) , but the effects of HAX-1 ablation in cardiac function have not been determined. Furthermore, ablation of HAX-1 in the mouse results in early death caused by neurological defects (17), precluding assessment of its role in the heart. Thus, we generated an inducible and cardiac specific knock-out model to explicitly assess the in vivo function of HAX-1. Ablation of HAX-1 in the adult heart resulted in increased SERCA2a Ca 2ϩ affinity and enhanced cardiomyocyte Ca 2ϩ cycling and contractility. Importantly, the regulatory effects of HAX-1 were mediated through controlling the binding of PLN to SERCA2a and modulating PLN inhibition (Fig. 4 , C and D, and Ref. 13 ). In fact, we observed that endogenous HAX-1 contributes to approximately 50% of the PLN inhibitory effects. There were no alterations on the maximal velocity of SERCA2a in HAX-1-deficient hearts, further supporting regulation of the transport system through PLN. These findings, combined with previous results in HAX-1 overexpression and HAX-1 heterozygous hearts (7), indicate that there is a close linear correlation (Fig. 6) 
Cardiac HAX-1 mediates half of phospholamban inhibition
Previous studies reported that maximal inhibition of SERCA2a and cardiac contractility is achieved by 2.5-fold overexpression of PLN, suggesting that ϳ40% of SERCA2a activity is functionally inhibited by PLN in wild-type hearts (9) . Consequently, the current results indicate that this fraction of inhibited SERCA2a by PLN could get further reduced to 20% in the absence of HAX-1 (Fig. 7A) . In addition, our findings reveal that the previously reported maximal inhibition (PLNOE) of SERCA2a and contractility by PLN was restricted by endogenous levels of HAX-1. Indeed, dual overexpression of HAX-1 and PLN sets a new maximal "functional saturation level" of SERCA2a inhibition. Extrapolation from this new maximal inhibition to WT hearts suggests that ϳ30% of SERCA2a is functionally inhibited by PLN/HAX-1 under basal conditions (Fig. 7B) . However, we must acknowledge that this estimate is limited by current knowledge and could be further modified through identification of additional regulatory factors.
The inability of PLN overexpression to diminish contractile parameters in the absence of HAX-1 (Fig. 5) demonstrates the nodal role of this protein in regulating the dynamic range of SERCA2a inhibition. This result also suggests that HAX-1 does not alter the binding affinity between PLN and SERCA2a. Further co-immunoprecipitation experiments would have provided additional information along these lines, but such studies are limited by the minimal lysate protein obtained from virally infected and cultured adult mouse cardiomyocytes. However, it is interesting to propose that our findings may reflect one or a combination of the following mechanisms: (a) HAX-1 may be necessary for displacing another unknown protein that modifies the PLN/SERCA2a interaction; (b) HAX-1 ablation may result in an unknown post-translational modification of SERCA2a, such that PLN regulation is functionally limited; and (c) PLN-SERCA2a regulation may involve functional units of either one PLN interacting with one SERCA2a molecule (18) or one PLN interacting with a SERCA2a dimer (19) . Thus, if HAX-1 modulates the balance between these functional units, then ablation of HAX-1 may favor the dimeric complex (2 SERCA2a: 1 PLN) and potentially saturate regulation of SERCA2a with a lower abundance of PLN.
Interestingly, phosphorylation of PLN results in its dissociation from HAX-1 (11) . As such, the inotropic and lusitropic effects of isoproterenol in the present study could be partially facilitated by loss of HAX-1 binding to PLN. In addition, the stimulatory effects of HAX-1 ablation may be partially attributed to loss of its co-chaperone protein Hsp90. Hsp90 was previously shown to interact with HAX-1 and facilitate its inhibitory effects on SR Ca 2ϩ uptake (15) . Thus, removal of HAX-1 may disrupt the compartmentalization of the HAX-1⅐Hsp90 complex, resulting in overall disinhibition of SERCA2a activity. Furthermore, several homologs of PLN have been identified (sarcolipin (20) , myoregulin (21), DWORF (22) , endoregulin (23) , and another-regulin (23) ) that regulate SERCA to varying degrees. However, these homologs do not contain AA residues 16 -22 of PLN (11) , which bind to HAX-1, and therefore may lack HAX-1 regulation. Nevertheless, it is intriguing to speculate that these PLN homologs may have their own undiscovered HAX-1 counterparts that are critical to their function.
In summary, the current study is the first to quantify the degree by which endogenous HAX-1 contributes to PLN inhibition and highlights HAX-1 as an important brake to control SERCA2a activity. Our findings also provide additional insights into the SERCA2a/PLN/HAX-1 regulatory axis and suggest that HAX-1 may be critical for amplification of the heart's 
responses to "flight or fight" situations as the heart strives to increase contractility and meet the demands of the periphery.
Experimental procedures

Animal models
HAX-1 inducible knock-out (HAXiKO) and their wild-type littermates were used in this study. HAXiKO mice were developed by crossing a floxed HAX-1 mouse (a gift from Dr. James Ihle, St. Jude, Memphis TN) with a transgenic mer/cre/mer containing the myosin heavy chain promoter (24) . To induce cre recombinase activity and HAX-1 ablation, 8-week-old male mice were treated with tamoxifen (40 mg/kg) for 14 days. Experiments were performed on 12-14-week-old male mice, which was 2-4 weeks after termination of tamoxifen treatment. The mice were bred and maintained in the animal facility at the University of Cincinnati according to the institutional and the National Institutes of Health guidelines for animal care and use (publication no. 8523).
Western blot analysis
The snap-frozen hearts were suspended in cell lysis buffer (Cell Signaling) containing 1 mM PMSF, protease inhibitor (Roche Applied Science), and phosphatase inhibitors I and II (Calbiochem) and homogenized. For immunoblotting, 5-120 g of protein was separated by SDS-PAGE gel electrophoresis using 6 -12% polyacrylamide gels followed by electrotransfer to 0.1-0.45-m nitrocellulose membranes. Blots were blocked in 5% milk and then probed overnight at 4°C using the following primary antibodies: monoclonal HAX-1 (1:1000; BD Biosciences), monoclonal PLN (1:5000; Thermo Fisher), monoclonal RyR2 (1:1000; Thermo Fisher), and polyclonal calsequestrin (1:5000; Thermo Fisher). Licor fluorescent mouse or rabbit specific secondary antibodies were used at a dilution of 1:10,000 and visualized by using Licor Odyssey imager. All protein levels were quantified with the Licor Image Studio. For each protein, the densitometric values from WT controls were arbitrarily converted to 100%, and the values of samples from the other groups were normalized accordingly and expressed as a percentage of WT. Calsequestrin was used as an internal standard.
Mouse myocyte isolation and viral infection
Isolation of mouse left ventricular myocytes was carried out as described previously (16) . Briefly, mouse hearts were excised from anesthetized (Euthasol, 200 mg/kg i.p.; Virbac AH, Inc.) adult mice, mounted in a Langendorff perfusion apparatus, and perfused with calcium-free Tyrode solution (140 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 10 mM glucose, and 5 mM HEPES, pH 7.4.) at 37°C for 3 min. Perfusion was then switched to the Tyrode solution containing liberase enzyme (0.25 mg/ml; Roche) for 8 -15 min. The left ventricular tissue was excised, minced, pipette-dissociated, and filtered through a 240-m screen. The cell suspension was then sequentially washed in 25, 100, and 200 M and 1 mM Ca 2ϩ -Tyrode, and resuspended in 1.8 mM Ca 2ϩ -Tyrode for further experimentation.
For viral infection, freshly isolated myocytes were plated on laminin-coated coverslips (10 g/ml) for 1 h at 5% CO 2 and 95% air at 37°C. After the attachment, cardiac myocytes were transduced with adenoviruses to express either ad.PLN or ad.GFP at a multiplicity of infection of 500 and incubated for 3 h at 37°C. Then medium was replaced with culture medium (DMEM containing 5 mg/liter ITS (bovine insulin, human transferrin and sodium selenite; Sigma), 100 units/ml penicillin streptomycin, 2 mM L-glutamine, 4 mM NaHCO 3 , 10 mM HEPES, 0.2% BSA, and 25 M blebbistatin (Cayman Chemical)). Experiments were performed 24 h after infection.
Measurements of mechanics and Ca 2؉ kinetics
Cell contractility and Ca 2ϩ transients were measured at room temperature (22-23°C) in separate experiments as previously described (13) . Myocytes were field-stimulated to contract by a Grass S5 stimulator through platinum electrodes placed alongside the bath (0.5 Hz, bipolar pulses with Cardiac HAX-1 mediates half of phospholamban inhibition voltages 50% above myocyte voltage threshold). Contractions of myocytes from random fields were assessed by video edge detection. For Ca 2ϩ transient measurements, the cells were loaded with Fura-2 (Fura-2 AM; 2 M; Thermo Fisher) and alternately excited at 340 and 380 nm by a Delta Scan dual-beam spectrophotofluorometer (Photon Technology International) at baseline conditions and upon rapid application of 10 mM caffeine (Sigma). Calcium transients were expressed as the 340/380-nm ratio of the resulting 510-nm emissions. Rapid application of 10 mM caffeine was used to induce release of SR Ca 2ϩ uptake assays were performed as previously described (12, 13) . Hearts from were frozen under liquid nitrogen and stored at Ϫ80°C until processed. Frozen hearts were homogenized in 50 mM KH 2 PO 4 , pH 7.0, 10 mM NaF, 1 mM EDTA, 0.3 M sucrose, 0.3 mM phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol. Ca 2ϩ uptake in whole-heart homogenates (0.1 mg/ml) was measured by a modification of the Millipore filtration technique. The reaction contained 40 mM imidazole, pH 7.0, 100 mM KCl, 5 mM MgCl 2 , 5 mM NaN 3 , 5 mM potassium oxalate, 0.5 mM EGTA, 1, M ruthenium red, and various concentrations of CaCl 2 to yield 0.02 to 5 M free A, an "old" scale based on previous data (9) using PLNOE as the reference point for maximal inhibition (100%), with PLNKO used as no inhibition (0%). B, new data suggest that dual overexpression of PLN with HAX-1 (PLNOE/HAXOE) inhibits SERCA2a more than PLNOE alone, which is used as the basis for a "new" maximal inhibition (100%) of SERCA2a. Based on the "old" scale, PLN was suggested to functionally inhibit 40% of SERCA2a in WT hearts (9) . The "new" scale demonstrates that this functional inhibition of SERCA by PLN/HAX-1 is closer to 30% in WT hearts. This schematic also demonstrates that in the absence of HAX-1 (HAXiKO), PLN has a limited dynamic range of inhibition.
Cardiac HAX-1 mediates half of phospholamban inhibition Ca 2ϩ . Homogenates were incubated at 37°C for 2 min in the above buffer, and the reaction was initiated by the addition of ATP (final concentration, 5 mM). The rates of Ca 2ϩ uptake were calculated by least squares linear regression analysis of 30-, 60-, and 90-s time points. The data were analyzed by nonlinear regression using ORIGIN (version 6.0) software.
Co-immunoprecipitations
Co-immunoprecipitations were performed as previously described (15) . Briefly, hearts were homogenized with 1ϫ cell lysis buffer (Cell Signaling Technology) supplemented with protease inhibitor mixture and phosphatase inhibitor mixture and was diluted to 1 mg/ml and incubated with antiSERCA2a (BD Biosciences) or IgG antibody (Santa Cruz Biotechnology) at 4°C overnight with rotation. Protein G Plusagarose beads (Santa Cruz Biotechnology) were added into the mixture and incubated for an additional 5 h, sedimented, and washed six times with the cell lysis buffer. Bead-bound proteins were dissociated in 2ϫ SDS and probed by Western blots. WT heart homogenate was used as positive control (input), and immunoprecipitate with anti-IgG Plus-agarose was used as negative control (IgG).
Statistical analysis
The data were expressed as the means Ϯ S.D. Comparisons between the means of two groups were performed by unpaired Student's t test. Multiple groups were analyzed by using two-way analysis of variance followed by Tukey's multiple comparisons. The results were considered statistically significant at p Ͻ 0.05. 
